Thank Australian you, for Thank to Jessica. remarkable of us U.S., in complete a progress joining review as year investors. today we you to morning and Good and good the transformation. afternoon our those
and indication. in year, as thickness skin the Over began wound strategic our past we the surgical full into leader business product This launched wounds core trauma company care. and a plan XXXX a multiproduct growth initiative single expanded we defects to evolved under from acute and treat our therapeutic
our January addition our it, in mission. April we aligning our portfolio stage our scalable a PermeaDerm, multiproduct portfolio. in infrastructure, a the first our transformation launched first began the to support To we announced these have in portfolio milestone In expansion. we efforts, pivotal with for By marking XXXX, XXXX, building setting
is headed. on shown Slide X we are who a and are of where mission cornerstone This we
future our is his how explain and significance success. Let it shaping me
Our acute Medical delivering as a AVITA therapeutic mission is leading company. care solutions. wound to position transformative
optimize recovery. statement healing, accelerating to technologies patient wound effectively in time this designed to the Our are are meaningful. Words
Let's this break down means. what
solutions like the care. Therapeutic our cure be ulcers, of it's ulcers burns, nor and or pressure put, means source. treat focus patients common car just rather industrial is unexpected defines gender, injuries, are as Simply of Acute wounds, palliative or such with we are burns. nature denominator fires not actively their of foot events or their accidents that it heal ethnicity leg nature diabetic shared age, victims forms their not our their patients, traumatic severe chronic event-driven not The or designed to our surgical traumatic or venous crashes, is wounds, not injuries. of patients the
burns fire road a recent attack injuries incident, to result be solo or These tragic all the in of multiple from Despite could traumatic Orleans. industrial injuries diverse injuries due patients worse, have scenarios, helps overall underscores expanded like faster behind quickly. product patients patients their of And care force our more not our a but and home mission importantly, more our to only portfolio. This return help costs, reduces power heal from terror their New these the a technologies ones loved events. an sustained driving to event health the
our we our product mission. X portfolio turn related that aligns markets with Slide explained serve the Please I as to see to how
optimizes RECELL how and product healing core recovery. it accelerates patient review our with patient start Let's and
lead faster, the the Additionally, techniques, demonstrates patients experience achieve significantly skin, AXX. hospital sparing, sample what foremost, that closure with traditional RECELL that evidence RECELL and feel and autologous physicians to substantial is sooner. it skin. Compared [ known donor to healthy is allowing First also ] less special using treated as RECELL grafting makes expands scarring less skin clinical autologous
The RECELL next-generation both burn combines RECELL is streamline and trauma outcomes with features its centers. simplify of resell to GO, and use very that in well. the our conversion system proven enhanced GO going
We XX% our total for of accounts unit center all over accounts volume. of converted our XX% approximately and burn trauma nearly have our of
our a As centimeters, up RECELL standard GO is area. square reminder, XX% processing each total which of body surface X,XXX to concrete kits roughly of
kit most for However, created a wound cognitive small X.X% to surface sledgehammer traumatic like using the or standard size centimeters a under clinicians a driving body This a difference XXX using wounds distinance nail. of are about square somewhat total a area. resell small treat
critical To care address our a XXX centimeters, under this, we square building RECELL wounds trauma for offering. in Mini gap GO designed
approval December on -- anticipated, Mini received As we XX. for RECELL GO
possibilities PermeaDerm, therapeutic are significant kit. sooner helping volume Mini like temporary a in biosynthetic a same uses patients lowering that RECELL QX. thereby overall centers during out treat go stays, our faster and and hospital care. GO GO burn portfolio healing and complementary feel supporting RECELL plays to of processing processing This It reduce trauma clinicians patients solutions strengthens Mini role currently the as a acute a further portfolio, with get in care Cohealyx Incidentally, rolling grafting. by go cost our before We unlocking standard wound wounds resell wound of dressing after home foundation is We of device resell the smaller and innovation
unique qualities take about the remind of I want PermeaDerm. a to you moment to
it wound airflow facilitating porous, promote the to drainage. healing while enabling to First, is exudate
levels, optimal unique is is for the adjust patient's conditions moisture ensuring each which flexible, healing needs. Next porosity lets wound to clinicians
which uniquely removing the effective. graft. allows progress, of lifting cover monitor it making the the the a rather the Finally, transparent -- dressing, it's skin skin without have clear progress view disrupt Practitioners to monitor potentially healing than graft it can clinicians or disturbing
FDA-cleared matrix Cohealyx matrix need wound Biosciences. approach step collagen-derived healing we is represents in a readiness. addressing further, codeveloped newly REGENITi dermal our breakthrough that dermal our a for Taking Cohealyx critical with accelerated graft the
graft demonstrated reducing for X XX just validated for a for days, the preclinical on our graft a in porcine It before Our is XX goal matrices and matrix eliminating and that to clear: days into readiness. bed days work skin wound when that In wound. need was is studies. used removal model, grafting integrates alternative the Cohealyx application material compared large in create dermal of number histologically, as a dermal ready a to the absorbs the
This full blood faster illustrate vessels important structure is the faster the to new readiness hospital significant of eventually cost regrowth, directly benefits to wounds, shorter and outcomes. and translates supports treating of into wounds. stays, patient provides thickness reduced XD To complexities healing, full the and wound. with the challenges tissue formation In thickness associated better a and it's Cohealyx that understand absorbed
thickness overnight. knee of connective layers and heal and missing tissue. causing severe quickly at integrity. thickness timely skin, and repopulate rebuild soft for open full own delayed Full a intervention. cells wounds skin injury scarring connective delayed infection a definition, superficial damage leaves the significant the all penetrates and structural often your the surgical Unlike the risk and abrasion, By to wound tissue the loss time lack healthy cells This necessary to of research tissue
it of let you. For me example, describe for standard care a X-stage is procedure, the
without and injuries why additionally, tissue. deep the tissue a or may loss unsightly using preparing the graft immediately not to could clean to skin tissue dermal first bed approach were damaged surgical perform heavy metrics be graph to the the insufficient from thickness or split connective you the reconstruct structured wound, thickness take close and outcome wound a due full likely the an lost resulting loss This a a to functionality bed wound scarring. is X-stage If there require of
healing of we may the data support important graft develop application U.S. also In such It tissue. study for at tissue a cases or across us environment. initiated base, of an Then have the excision infection currently involve multiple of damaged which clinical IRB thickness a post-market bite dermal human severe And this, to known of the possibly is Cohealyx. to PermeaDerm shark as protect a the X, launch To use approval sites bacterial is the Cohealyx closure. split to pending clinical accomplish loss, of by treatment Cohealyx as followed necrotizing to build
study study as performance objective to Cohealyx data dermal from performance OPC alternative design criteria This gains published majors. an uses known benchmark
to including alternative study dermal phase demonstrate to We readiness value anticipate this will and XX-week graft compared reinforcing We to are days that measuring go to shorter period, matrices, graft home. key X-day outcomes the closure readiness, over accelerated days and closure wound overall a further Cohealyx. to time of
results ahead fact, already So X many completed have our case shown been with Cohealyx preclinical has consistent of of patients findings. the already promising our formal enrollment first in
was grafting, over the was Let's turn she while mid-January, a discharged B. In highlights in image the seen Image C, Ohio woman burn as Cohealyx, She to as third consistent at of preclinical A. look application of her a in wound Within this day Slide at an was stove findings. the received as Medical for shown degree shown Wexner XX-year-old with State case. treated cooking her sustained weeks, X.X to Image she where our hospital. Center By X, from ready #X
extended more he medical According case she alternative room. X, been it why allow According the Slide not month. reduce treating metrics, will spends operating already the that was patients changer an to in treated dermal of because community highlights of hospital a clinicians, in to treat time in physicians started acute Cohealyx with see likely of has a a physician, would wounds. amount game the can treatment how Cohealyx one our on to does only to it easy to of but had as stay the to patient have our This hospital, believes recognize as you the use
a ensuring cost and lowering point patients return new care, time of standard treating acute to Quite and a of turning is the honestly, breakthrough severe for Medical while wound home. injuries healing for this setting in outcome care, for the AVITA a
strategically X-stage of playing of PermeaDerm roles thickness of as ones, By portfolio full integral total and their wounds by in a an -- on XX% roles patient a X. into covering care the standard for fit for X-stage burn within consider area. body care playing integral Cohealyx Slide illustrated thickness our with full service standard
of a burn. First, the surgical procedure the with begins excision
alternative from bed, Next, ready, which dermal days graft to bed Cohealyx After PermeaDerm The temporize the than XX wound is wound for the to there matrices. proceed of wound X is is applied infection, time. to regrowth and clinicians tissue to is to to free the later, the improve determined is allowing wound short second meaning tissue necrotic faster could grafting. sufficient X a days period applied prepare wound the for stage. bed Approximately have be
stage RECELL skin begins a cells newly tissue. combined sprawl based thickness split meshed with over generated second the with autograft The
graft skin the wounds. autologous and expands aid the PermeaDerm reminder, RECELL of cells in [ the XX Remember the is separately significantly closure to skin supports layer site applied the As that used compared and resell a applied sample healing less resell to ] of newly hopefully, definitive over autografting process both [indiscernible] to Breon procedures. then traditional both donor
This the wound expanding leave This improves continuously determine integrated is when AVITA patient opportunity. Medical's ready assessed the clinical market is hospital. to outcomes significantly while approach to
total at patient. market Let's available per the look potential
For Cohealyx is same applied wound, $X,XXX a body adds patient potential price XX% for the the XX,XXX $X,XXX aggregate, economic substantial to price PermeaDerm to selling increases In accelerating is providing $XX,XXX, XX% RECELL benefits to to average and area products $XX,XXX. by the average home. X the the selling while are between together, the it and the When $XX,XXX. to between total the selling $X,XXX average return wound, to ranges potential when surface is price all clinical time used $XX,XXX for addressing. all
using Cohealy model total additional Center Wexner commercial the an Medical X, discussed increase in launch resell point, Medical. demonstrated earlier, we adoption case inventory in initiate the also will On consignment addressable full large be to Cohealyx as with tracking hospital wounds, for of independently and last can market RFID simplify AVITA management. for One the of of used resulting April our
and the FDA. RFID reps Our hospital, inventory track sales reader our will the accounting use for internal the
time addressable for consignment that model will current million a approximate value benefits total TAM these and burn With just for faster. solution. below we pricing, positioning further same a committee our coupled the within it of reduced graft TAM PermeaDerm with plan believe Cohealyx us are million on key process or top XXX-plus add analysis Cohealyx, to and to progress market the price a TAM, burn Competitive as We we help to through nearly billion leaders, the the RECELL centers. $XXX $X $XXX in centers market, value-driven
TAM. in provides has $X.X In $X.X and in wounds. RECELL a the TAM targeting trauma thickness billion a Cohealyx alone. the $XXX billion U.S. in TAM PermeaDerm million $X.XX centers, Medical in full now In adds opportunity of billion potential combined AVITA TAM, contributes aggregate,
Let's RECELL Two ago, was TAM in moment solely $XXX years take total and our million, centers. backwards. a look burn for
received full to FDA allowing from enter for Just dramatically $X.X XX and centers. by a billion the a we us TAM TAM burns $XXX which trauma market. the we've approval in gone TAM center our million time, trauma months ago, thickness expanded and In indication burns to that
Looking by the GO adoption. number we number Cohealyx clear, we approximately thickness Union Number for expand GO RECELL one, markets be middle in RECELL our will in the Number X, Number annually. trauma acute year, and during up Australia. This focused Europe on ahead, roll our strategy Trauma or to the clear: not chronic first RECELL Grant, GO is will opening wounds out Mark To quarter targeting body Center to full wounds wound XXX,XXX market by of the two, CE the be Mini X, centers. commercially. chronic finally, out continue X, European notified launch roll and PermeaDerm expect the expand centers.
committed of year the during achieving of and cash profitability to XXXX. QX the generating remain flow We second half in free GAAP
transformational was a In summary, year. XXXX
expanded revolutionize Mini, in million billion for of $XXX portfolio, single therapeutic we RECELL which to across the and our and centers I product focused trauma RECELL with care to acute both support team their GO a $X.X TAM standard TAM thank product includes customers now burn a treatment. unwavering and as a RECELL, want acute wound burns us continue taken wound and therapeutic care has Cohealyx Our GO, on shareholders solely from PermeaDerm centers. to
David our at With for David? that, to I closer and a will results look guidance. turn financial over the call
